期刊文献+

58例喉癌组织蛋白酶B表达及临床特征分析 被引量:1

Relationship between expression of cathepsin B and clinical feature of larynx cancer
下载PDF
导出
摘要 目的探讨组织蛋白酶B(cathepsin B,CB)表达与喉癌发生、发展及浸润转移的关系。方法喉癌组58例肿瘤组织,其中临床分期Ⅰ期7例,Ⅱ期14例,Ⅲ期26例,Ⅳ期11例;病理分级高分化15例,中分化22例,低分化21例。另选择19例癌旁组织作对照。采用免疫组织化学SABC染色法和原位杂交法检测CB蛋白表达和mRNA水平情况。结果喉癌组CB蛋白定位于癌细胞胞浆,阳性率(44/58,75.9%)显著高于癌旁组(1/19,5.3%),淋巴转移组显著高于无转移组,不同临床分期阳性率显著不同。CB mRNA阳性率(35/58,60.3%)显著高于癌旁组(0/19),临床特征分析与CB蛋白相同。结论CB在喉癌组织中蛋白和mRNA水平均为高表达,CB表达与喉癌的发生、发展及浸润转移有关。 Objective To explore the expression regulation of cathepsin B in different period of larynx cancer. Methods Fiftyeight specimens of the patients sufferred from larynx cancer were included in this experiment. Among them,Tcases were in clinical stage I , 14 in stage Ⅱ ,26 in stage m and 11 in stage IV. Another 19 latero-tissue away from larynx cancer were included in the control group. The expression of cathepsin B was detected with the technology of immunohistochemistry staining and in situ hybridization. Results In the cancer group,the cathepsin B protein was expressed in the cell cytoplasm, the expressing rate of cathepsin B protein was markedly higher than that in the control group. The expressing rate of cathepsin B protein in the lymphatic metastasis group was higher than that in the no lymphatic metastasis group. In the different clinical stage, the expressing rates of cathepsin B protein were different. In the cancer group,the cathepsin B mRNA was expressed in the cell cytoplasm, the expressing rate of cathepsin B mRNA was markedly higher than that in the control group. Conclusion The abnormal high expression of cathepsin B protein and mRNA plays an important role in the occurrence of larynx cancer. The expression of cathepsin B has relationship with the progress and infihration of larynx cancer.
出处 《重庆医学》 CAS CSCD 2007年第24期2533-2534,2537,I0026,共4页 Chongqing medicine
关键词 喉癌 组织蛋白酶B 免疫组织化学 原位杂交 larynx cancer cathepsin B immunohistochemistry in situ hybridization
  • 相关文献

参考文献8

  • 1Ricciardelli C, Rodgers RJ. Extracellular matrix of ovarian tumors[J]. Semin Reprod Med, 2006,24(4):270.
  • 2Addison C. Modulation of response to tumor therapies by the extracellular matrix[J]. Future Oncol, 2006, 2(3): 417.
  • 3Gopal P, Rehman RU, Chadha KS, et al. Matrigel influences morphology and cathepsin B distribution of prostate cancer PC3 cells[J]. OncolRep,2006,16(2): 313.
  • 4Coburn NG,Clarke PE, Chung MA, et al. A novel approach to T classification in tumor node-metastasis staging of breast cancer[J]. AmJ Surg,2006,192(4):434.
  • 5Liu WM, Zhang XA. KAI1/CD82, a tumor metastasis suppressor[J]. Cancer Lett,2006,240(2) :183.
  • 6Vasiljeva O, Papazoglou A, Kruger A, et al. Tumor cell- derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer[J].Cancer Res,2006,66(10): 5242.
  • 7Guzinska UK. MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer (CRC)[J]. Anticancer Res, 2006,26(2B) : 1589.
  • 8Rodriguez J, Vazquez J,Corte MD, et al. Clinical significance of cathepsin D concentration in tumor cytosol of primary breast cancer[J]. Int J Biol Markers, 2005,20 (2) : 103.

同被引文献4

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部